Nasdaq · CIK 0002040475
DMII Drugs Made In America Acquisition II Corp.
Insider trading from SEC Form 4. Last filing Oct 17, 2025.
Drugs Made In America Acquisition II Corp. (DMII) has 6 SEC Form 4 filings on file from 6 insiders, the latest filed on Oct 17, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Drugs Made In America Acquisition II Corp., scored.
Transactions
Every row filed, 12 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 26, 2025 | Catherine Do director | JOther Ordinary shares | +100,000 | - | - | 100,000 | Oct 17, 2025 |
| Sep 26, 2025 | Myron W. Shulgan director | JOther Ordinary shares | +100,000 | - | - | 100,000 | Oct 2, 2025 |
| Sep 26, 2025 | Sridhar G. Prasad director | JOther Ordinary shares | +100,000 | - | - | 100,000 | Oct 1, 2025 |
| Sep 26, 2025 | Drugs Made In America Acquisition II LLC owner | POpen-market purchase Ordinary shares | +700,000 | - | - | 15,075,000 | Oct 1, 2025 |
| Sep 26, 2025 | Lynn Stockwell CEO and Exe. Chair of Board | POpen-market purchase Ordinary sharesindirect: See Footnote | +700,000 | - | - | 15,075,000 | Oct 1, 2025 |
| Sep 26, 2025 | Glenn C. Worman CFO | JOther Ordinary shares | +100,000 | - | - | 100,000 | Oct 1, 2025 |
| Sep 26, 2025 | Drugs Made In America Acquisition II LLC owner | JOther Ordinary shares | -400,000 | - | - | 14,675,000 | Oct 1, 2025 |
| Sep 26, 2025 | Lynn Stockwell CEO and Exe. Chair of Board | JOther Ordinary sharesindirect: See Footnote | -400,000 | - | - | 14,675,000 | Oct 1, 2025 |
| Sep 26, 2025 | Drugs Made In America Acquisition II LLC owner | SOpen-market sale Ordinary shares | -7,966,667 | - | - | 6,708,333 | Oct 1, 2025 |
| Sep 26, 2025 | Lynn Stockwell CEO and Exe. Chair of Board | SOpen-market sale Ordinary sharesindirect: See Footnote | -7,966,667 | - | - | 6,708,333 | Oct 1, 2025 |
| Sep 26, 2025 | Drugs Made In America Acquisition II LLC owner | POpen-market purchase Rights to receive ordinary sharesderivative | +700,000 | - | - | 700,000 | Oct 1, 2025 |
| Sep 26, 2025 | Lynn Stockwell CEO and Exe. Chair of Board | POpen-market purchase Rights to receive ordinary sharesderivativeindirect: See Footnote | +700,000 | - | - | 700,000 | Oct 1, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Catherine Dodirector
- Drugs Made In America Acquisition II LLCowner
- Sridhar G. Prasaddirector
- Myron W. Shulgandirector
- Lynn StockwellCEO and Exe. Chair of Board
- Glenn C. WormanCFO
Questions about DMII
Answered from the filings on this page, as of the latest one.
Are insiders buying DMII?
No. In the last 90 days no insider at Drugs Made In America Acquisition II Corp. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade DMII on the open market?
No open-market trade has been scored at Drugs Made In America Acquisition II Corp.. The latest Form 4 on file was filed on Oct 17, 2025 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Drugs Made In America Acquisition II Corp.?
6 people have filed a Form 4 at Drugs Made In America Acquisition II Corp., among them Catherine Do (director), Drugs Made In America Acquisition II LLC (10% owner), Sridhar G. Prasad (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.